A Phase I Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 21 Jan 2015
At a glance
- Drugs Luminespib (Primary) ; Capecitabine
- Indications Solid tumours
- Focus Adverse reactions
- 27 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 31 Mar 2014 Planned End Date changed from 1 Dec 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov.
- 21 Jun 2013 Planned end date changed from 1 Apr 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.